Aurinia Pharmaceuticals Inc. (AUPH) — closed signal from September 8, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 7, 2025 — +26.4% at the close.
Predicted vs. what happened
What happened
Reached its target in 57 days.
The thesis — published September 8, 2025
AUPH's business and investor mood are improving. The price has calmed, so buying small dips can make sense. Analysts raised next-quarter profit estimates by 28%, and Q2 sales were $70M, both pointing to momentum for LUPKYNIS. As interest in biotech slowly returns, near-term upside seems possible. Still, this sector can swing, so keep positions modest and wait for confirmation.
Primary drivers
- Analysts raised profit forecasts; recent sales came in better than expected
- Price behavior improving, with space for the stock to strengthen further
- LUPKYNIS sales look steady, supporting longer-lasting business strength
- Fresh news: estimates up 28% and Q2 sales of $70M showed solid progress
How it played out
AUPH: target reached in 57 days
Lyra published AUPH at $12.36 on September 8, 2025, with 25% expected growth. The thesis pointed to improving business and investor mood, calmer price action, raised next-quarter profit estimates of 28%, Q2 sales of $70M, and steady LUPKYNIS sales. It also noted that biotech could swing.
Inside the window, the stock reached the $15.45 target in 57 days. It peaked at $16.48 on November 26, 2025, with a 33.3% gain. By December 7, 2025, it ended at $15.62. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.